Osteoporosis, Endocrinology, Internal medicine, Parathyroid hormone and Bone density are her primary areas of study. Her Osteoporosis research is multidisciplinary, relying on both Surgery and Urology. Felicia Cosman combines subjects such as Hip fracture and Denosumab with her study of Surgery.
In her research on the topic of Endocrinology, Calcitonin, Oral administration, Estrogen and Nasal administration is strongly related with Calcium. Her Internal medicine study which covers Skeleton that intersects with Bone tissue and Menopause. Her Parathyroid hormone study incorporates themes from Cortical bone, Iliac crest, Anabolism, Biopsy and Resorption.
Her scientific interests lie mostly in Osteoporosis, Internal medicine, Endocrinology, Bone mineral and Bone density. The various areas that Felicia Cosman examines in her Osteoporosis study include Placebo, Surgery and Urology. Her study in Bone remodeling, Parathyroid hormone, Bone resorption, Abaloparatide and Estrogen falls within the category of Internal medicine.
Her research investigates the connection between Endocrinology and topics such as Calcium metabolism that intersect with issues in Urinary calcium. Her studies in Bone mineral integrate themes in fields like Randomized controlled trial and Tibia. Her studies deal with areas such as Physical therapy, Nuclear medicine and Anatomy as well as Bone density.
The scientist’s investigation covers issues in Osteoporosis, Internal medicine, Abaloparatide, Placebo and Teriparatide. Her Osteoporosis research is multidisciplinary, incorporating elements of Postmenopausal women, Incidence and Urology. Much of her study explores Internal medicine relationship to Endocrinology.
Her Abaloparatide research entails a greater understanding of Parathyroid hormone. Her Placebo research incorporates elements of Relative risk reduction and Surgery. Her Teriparatide research incorporates themes from Cancellous bone, Anabolism, Anabolic Agents, Bone density and Denosumab.
Her primary areas of investigation include Osteoporosis, Internal medicine, Placebo, Bone mineral and Abaloparatide. She has researched Osteoporosis in several fields, including Physical therapy and Treatment goals. Her Internal medicine research is mostly focused on the topic Femoral neck.
Her research in Bone mineral focuses on subjects like Incidence, which are connected to Clinical trial and Risk factor. Her Abaloparatide course of study focuses on Randomized controlled trial and Endocrinology. Her biological study spans a wide range of topics, including Teriparatide and Surgery.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black;Pierre D. Delmas;Richard Eastell;Ian R. Reid.
The New England Journal of Medicine (2007)
Clinician’s Guide to Prevention and Treatment of Osteoporosis
F. Cosman;S. J. de Beur;M. S. LeBoff;E. M. Lewiecki.
Osteoporosis International (2014)
Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research
Elizabeth Shane;David Burr;Peter R. Ebeling;Bo Abrahamsen.
Journal of Bone and Mineral Research (2011)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
F. Cosman;D. B. Crittenden;J. D. Adachi;N. Binkley.
The New England Journal of Medicine (2016)
The 2017 hormone therapy position statement of The North American Menopause Society.
Jo Ann V. Pinkerton;Fernando Sánchez Aguirre;Jennifer Blake;Felicia Cosman.
Anabolic Actions of Parathyroid Hormone on Bone
David W. Dempster;Felicia Cosman;May Parisien;Victor Shen.
Endocrine Reviews (1993)
Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
Robert Lindsay;Jeri Nieves;Carmelo Formica;Emily Henneman.
The Lancet (1997)
The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M Black;Ian R Reid;Steven Boonen;Christina Bucci-Rechtweg.
Journal of Bone and Mineral Research (2012)
Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study.
David W. Dempster;David W. Dempster;Felicia Cosman;Felicia Cosman;Etah S. Kurland;Hua Zhou.
Journal of Bone and Mineral Research (2001)
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial
Paul D. Miller;Gary Hattersley;Bente Juel Riis;Gregory C. Williams.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: